Trial Profile

A Randomized, Open-Label, Cross-Over, Study to Evaluate the Inhibitory Effect of Clopidogrel, EC Aspirin 81 mg and EC Omeprazole 40 mg All Dosed Concomitantly and PA32540 and Clopidogrel Dosed Separately on Platelet Aggregation in Healthy Volunteers.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 02 Sep 2013

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aspirin/omeprazole (Primary) ; Aspirin; Clopidogrel; Omeprazole
Indications Cardiovascular disorders; Embolism and thrombosis; NSAID-induced gastrointestinal damage
Focus Pharmacodynamics; Pharmacogenomic
Acronyms Co-Rx

29 Aug 2012 Results have been presented at the European Society of Cardiologists 2012 Congress according to a POZEN media release.
16 Mar 2012 Official Title amended as reported by ClinicalTrials.gov.
16 Mar 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01557335).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com